[1]周振发,胡翠芬,石冬梅,等.急性前壁ST段抬高型心肌梗死患者血清胸腺肽α1与心功能相关性研究[J].介入放射学杂志,2024,33(07):717-722.
ZHOU Zhenfa,HU Cuifen,SHI Dongmei,et al.Correlation between serum thymosin α1 and cardiac function in patients with acute anterior wall ST-segment elevation myocardial infarction[J].journal interventional radiology,2024,33(07):717-722.
点击复制
急性前壁ST段抬高型心肌梗死患者血清胸腺肽α1与心功能相关性研究(
)
《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]
- 卷:
-
33
- 期数:
-
2024年07
- 页码:
-
717-722
- 栏目:
-
心脏介入
- 出版日期:
-
2024-07-23
文章信息/Info
- Title:
-
Correlation between serum thymosin α1 and cardiac function in patients with acute anterior wall ST-segment elevation myocardial infarction
- 作者:
-
周振发; 胡翠芬; 石冬梅; 刘 亮; 沈成兴
-
- Author(s):
-
ZHOU Zhenfa; HU Cuifen; SHI Dongmei; LIU Liang; SHEN Chengxing.
-
Department of Cardiology, Affiliated Shanghai Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200233, China
-
- 关键词:
-
【关键词】 急性前壁ST段抬高型心肌梗死; 胸腺肽α1; 左心室射血分数
- 文献标志码:
-
A
- 摘要:
-
【摘要】 目的 探讨急性前壁ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后住院期间血清胸腺肽(Tα1)水平与左心室射血分数(LVEF)的相关性。方法 纳入2019年12月至2022年2月在上海市第六人民医院诊治的急性前壁STEMI患者74例(急性前壁STEMI组),无心肌梗死患者38例(对照组)。根据PCI开通前降支后住院期间LVEF值,将急性前壁STEMI患者分为LVEF<50%组(33例)和LVEF≥50%组(41例)。采用酶联免疫吸附试验(ELISA)法测定患者血清Tα1水平并进行组间比较。采用logistic回归分析Tα1水平与LVEF相关性。绘制急性前壁STEMI患者PCI后Tα1水平对心功能预测价值的受试者工作特征曲线(ROC)。结果 急性前壁STEMI LVEF≥50%组患者血清Tα1水平显著高于LVEF<50%组(P=0.032)。PCI后住院期间血清Tα1与LVEF呈正相关。logistic回归分析表明,Tα1水平是PCI后急性前壁STEMI患者LVEF<50%的独立预测因素。血清Tα1水平预测急性前壁STEMI患者住院期间LVEF≥50% ROC曲线下面积为0.644(P=0.034);联合肌钙蛋白Ⅰ峰值、NT-proBNP峰值预测急性前壁STEMI患者住院期间LVEF<50% ROC曲线下面积分别为0.780(P<0.01)、0.702(P=0.003)。以急性前壁STEMI患者血清Tα1水平中位数为界,PCI后血清Tα1水平>2 890 ng/L 患者LVEF≥50%比例较高。结论 急性前壁STEMI患者血清Tα1水平与PCI后住院期间LVEF值密切相关,是急性前壁 STEMI 患者PCI后心功能改善的独立预测因素,有望成为开通罪犯血管后预测急性前壁STEMI心功能改善的新指标。
参考文献/References:
[1] Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics- 2019 update: a report from the American Heart Association[J]. Circulation, 2019, 139: e56- e528.
[2] 《中国心血管健康与疾病报告2022》编写组. 《中国心血管健康与疾病报告2022》概述[J]. 中国心血管病研究, 2023,21:577- 600.
[3] 《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究, 2021, 19:582- 590.
[4] Byrne RA,Rossello X,Coughlan JJ,et al. 2023 ESC guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44: 3720- 3826.
[5] Alabas OA, Jernberg T, Pujades- Rodriguez M, et al. Statistics on mortality following acute myocardial infarction in 842 897 Europeans[J]. Cardiovasc Res, 2020, 116: 149- 157.
[6] Klancik V, Pesl L, Neuberg M, et al. Long- term follow- up in patients with ST- segment elevation myocardial infarction who underwent primary percutaneous coronary intervention[J]. Eur Heart J Suppl, 2022, 24: B16- B22.
[7] Yasuda S,Honda S,Takegami MS,et al. Contemporary antiplatelet therapy and clinical outcomes of Japanese patients with acute myocardial infarction: results from the prospective Japan acute myocardial infarction registry (JAMIR)[J]. Circ J, 2019, 83: 1633- 1643.
[8] 叶 健,席 鑫,汪 谞,等. 急性前壁心肌梗死PCI术后肾动脉去交感神经术对心功能影响的临床研究[J]. 介入放射学杂志, 2022, 31:550- 554.
[9] Salari N, Morddarvanjoghi F, Abdolmaleki A, et al. The global prevalence of myocardial infarction: a systematic review and meta- analysis[J]. BMC Cardiovasc Disord, 2023, 23: 206.
[10] Nishimoto Y, Inohara T, Kohsaka S, et al. Changing trends in mechanical circulatory support use and outcomes in patients undergoing percutaneous coronary interventions for acute coronary syndrome complicated with cardiogenic shock: insights from a nationwide registry in Japan[J]. J Am Heart Assoc, 2023: e031838.
[11] Yildiz I, Rencüzogullar I, Karabag Y, et al. Predictors of left ventricular ejection function decline in young patients with ST- segment elevation myocardial infarction[J]. Rev Assoc Med Bras (1992), 2022, 68: 802- 807.
[12] Park S,Ahn JM,Kim TO,et al. Revascularization in patients with left main coronary artery disease and left ventricular dysfunction[J]. J Am Coll Cardiol, 2020, 76: 1395- 1406.
[13] Syyli N,Hautamaki M,Antila KR,et al. Left ventricular ejection fraction adds value over the GRACE score in prediction of 6- month mortality after ACS: the MADDEC study[J]. Open Heart, 2019, 6: e001007.
[14] Quagliata M, Papini AM, Rovero P. Therapeutic applications of thymosin peptides: a patent landscape 2018- present[J]. Expert Opin Ther Pat, 2023, 33: 865- 873.
[15] Gladka MM, Johansen AKZ, van Kampen SJ, et al. Thymosin β4 and prothymosin α promote cardiac regeneration post- ischaemic injury in mice[J]. Cardiovasc Res, 2023, 119: 802- 812.
[16] Gladka MM,Kohela A,Molenaar B,et al. Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2- dependent manner[J]. Nat Commun, 2021: 84.
[17] Guo QY,Yang JQ,Feng XX,et al. Regeneration of the heart: from molecular mechanisms to clinical therapeutics[J]. Mil Med Res, 2023, 10: 18.
[18] Goldstein AL,Slater FD,White A. Preparation,assay,and partial purification of a thymic lymphocytopoietic factor(thymosin)[J]. Proc Natl Acad Sci U S A, 1966, 56: 1010- 1017.
[19] Liu Y,Pan Y,Hu Z,et al. Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells[J]. Clin Infect Dis, 2020, 71: 2150- 2157.
[20] Qadir A,Jahan S,Aqil M,et al. Phytochemical- based nano- pharmacotherapeutics for management of burn wound healing[J]. GELS, 2021, 7: 209.
[21] Munshaw S,Bruche S,Redpath AN,et al. Thymosin β4 protects against aortic aneurysm via endocytic regulation of growth factor signaling[J]. J Clin Invest, 2021: 131 :e127884.
[22] Cannavo A,Rengo G,Liccardo D,et al. Prothymosin alpha protects cardiomyocytes against ischemia- induced apoptosis via preservation of Akt activation[J]. Apoptosis, 2013, 18: 1252- 1261
[23] Tao N, Xu X, Ying Y, et al. Thymosin α1 and its role in viral infectious diseases: the mechanism and clinical application[J]. Molecules, 2023, 28: 3539.
[24] Barcia MG, Castro JM, Jullien CD, et al. Prothymosin alpha is phosphorylated by casein kinase- 2[J]. FEBS Lett, 1992, 312: 152- 156.
[25] Renga G, Bellet MM, Pariano M, et al. Thymosin α1 protects from CTLA- 4 intestinal immunopathology[J]. Life Sci Alliance, 2020, 3: e202000662.
[26] Sikking MA,Stroeks S,Marelli- Berg F,et al. Immunomodulation of myocardial fibrosis[J]. JACC Basic Transl Sci, 2023, 8: 1477- 1488.
[27] Zacchigna S, Martinelli V, Moimas S, et al. Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction[J]. Nat Commun, 2018, 9: 2432.
备注/Memo
- 备注/Memo:
-
(收稿日期:2024- 01- 31)
(本文编辑:谷 珂)
更新日期/Last Update:
2024-07-23